New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 12, 2012
14:19 EDTIPXLFDA delay of Impax's Rytary should have little impact on outlook, says Needham
After the FDA extended the PDUFA for Impax's Rytary by three months but didn't request any new clinical trials, Needham expects the move to little impact on the outlook of investors, who had expected the drug to be approved with little difficulty. The firm expects the drug to be approved but believes that peak sales will be below the company's guidance. Needham maintains a Hold rating on the shares.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
10:01 EDTIPXLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:35 EDTIPXLImpax upgraded to Buy from Hold at WallachBeth
Subscribe for More Information
06:58 EDTIPXLImpax upgraded to Buy from Hold at Needham
Subscribe for More Information
October 9, 2014
07:21 EDTIPXLImpax to host conference call
Subscribe for More Information
06:13 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information
06:11 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use